Aetas Pharma Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

Aetas Pharma General Information

Description

Developer of cardiac and renal ailment drugs intended to better treat arrhythmias and overactive bladders. The company develops drugs that improve cardiac and renal functions and is engaged in the development of therapeutic agents for atrial fibrillation in heart disease, enabling clinicians to provide patients with better treatment for heart and kidney diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 1-7 Kanda Ogawacho
  • Chiyoda-ku
  • Tokyo, 101-0052
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1-7 Kanda Ogawacho
  • Chiyoda-ku
  • Tokyo, 101-0052
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aetas Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 01-Jun-2026 Completed Clinical Trials - Phase 2
4. Later Stage VC 01-Jan-2021 Completed Clinical Trials - Phase 2
3. Later Stage VC 31-May-2019 Completed Clinical Trials - Phase 2
2. Later Stage VC 30-Nov-2016 Completed Startup
1. Seed Round 01-Jan-2015 Completed Startup
To view Aetas Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Aetas Pharma Patents

Aetas Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4019089-A1 Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative Inactive 22-Jul-2019
EP-4019089-A4 Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative Inactive 22-Jul-2019
US-12252483-B2 Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative Active 22-Jul-2019
US-20220324856-A1 Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative Active 22-Jul-2019
WO-2021015221-A1 Method for producing optically active 1, 4-benzothiazepine-1-oxide derivative Inactive 22-Jul-2019 C07D417/06
To view Aetas Pharma’s complete patent history, request access »

Aetas Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aetas Pharma FAQs

  • When was Aetas Pharma founded?

    Aetas Pharma was founded in 2000.

  • Where is Aetas Pharma headquartered?

    Aetas Pharma is headquartered in Tokyo, Japan.

  • What is the size of Aetas Pharma?

    Aetas Pharma has 10 total employees.

  • What industry is Aetas Pharma in?

    Aetas Pharma’s primary industry is Drug Discovery.

  • Is Aetas Pharma a private or public company?

    Aetas Pharma is a Private company.

  • What is Aetas Pharma’s current revenue?

    The current revenue for Aetas Pharma is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process